Yuwen D, et al. - Researchers investigated whether circulating exosomal miRNAs have a role in the prediction of treatment response to platinum-based chemotherapy in patients with non–small cell lung cancer (NSCLC). HiSeq deep-sequencing analyses were performed on serum pool samples from platinum-resistant or platinum-sensitive patients by using circulating exosomal miRNAs. Furthermore, the predictive utility of 6 exosomal miRNAs were further validated by means of qRT-PCR in 170 serum samples of patients with advanced NSCLC. According to findings, circulating exosomal miR-425-3p was identified as a potential biomarker for improved predictions of the clinical response to platinum-based chemotherapy in patients with NSCLC.